Anzeige
Mehr »
Login
Montag, 03.06.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
East Africa Metals: Neues All-Time-High - die 276% Chance jetzt nutzen?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema VYNE THERAPEUTICS INC.

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
09.05.VYNE Therapeutics Inc. - 10-Q, Quarterly Report1
09.05.Vyne Therapeutics Inc reports results for the quarter ended in January - Earnings Summary1
09.05.VYNE Therapeutics Inc. - 8-K, Current Report1
01.05.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting2
01.03.VYNE Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
01.03.VYNE Therapeutics Inc. - 10-K, Annual Report1
29.02.VYNE Therapeutics Inc. - 8-K, Current Report1
29.02.VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update1852023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate...
► Artikel lesen
21.02.VYNE Therapeutics Inc.: VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference1
10.01.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo348VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
► Artikel lesen
03.01.VYNE Therapeutics Inc. - 8-K, Current Report1
13.12.23VYNE Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.12.23VYNE Therapeutics Inc. - 8-K, Current Report1